The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker
Abstract
BACKGROUND: The widespread use of prostate‐specific antigen (PSA) screening has had a tremendous impact on all aspects of the management of prostate carcinoma. Although PSA‐based screening has resulted in a stage migration to more organ‐confined tumors at the time of diagnosis, and has been temporally associated with a decrease in prostate carcinoma mortality, PSA screening is imperfect. A recent analysis of results from the Prostate Cancer Prevention Trial (PCPT) has provided insight into the positive predictive value of PSA in the so‐called “normal” range. METHODS: The history of the discovery, initial studies, and subsequent widespread application of PSA screening is reviewed. RESULTS: The application of PSA for screening preceded the development of current prostate biopsy techniques and an upper limit of normal was established without complete disease ascertainment. More recent modifications of PSA‐based screening have been adopted clinically without sufficient validation. With current methods, overdiagnosis of clinically unimportant disease almost certainly occurs and high‐grade, aggressive disease may not be detected sufficiently early to allow successful treatment. CONCLUSIONS: To the authors' knowledge, the optimal upper limit of normal for PSA for prostate carcinoma screening is unknown. New biomarkers of disease are needed; these must be linked with disease prognosis and must be validated in rigorously designed clinical trials. Cancer 2004. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Self-citationProstate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171501 · Cited by 2,451
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Self-citationMeasurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Random Systematic Versus Directed Ultrasound Guided Transrectal Core Biopsies of the Prostate
Hodge, K. K., McNeal, J. E., Terris, M. K., & Stamey, T. A. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)38664-0 · Cited by 1,571
Oesterling, J. E. (1993) · JAMA · doi:10.1001/jama.270.7.860 · Cited by 1,266
Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease
Carter, H. B. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160073037 · Cited by 1,096
Catalona, W. J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510080052031 · Cited by 998
Results of Conservative Management of Clinically Localized Prostate Cancer
Chodak, G. W., Thisted, R. A., Gerber, G. S., Johansson, J.-E., Adolfsson, J., Jones, G. W., Chisholm, G. D., Moskovitz, B., Livne, P. M., & Warner, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300403 · Cited by 928
Cited by
Protein Glycosylation in Cancer
Stowell, S. R., Ju, T., & Cummings, R. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040438 · Cited by 873
Risks and benefits of dietary isoflavones for cancer
Andres, S., Abraham, K., Appel, K. E., & Lampen, A. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2010.541900 · Cited by 168
Blaszczyk, N., Masri, B. A., Mawji, N. R., Ueda, T., McAlinden, G., Duncan, C. P., Bruchovsky, N., Schweikert, H.-U., Schnabel, D., Jones, E. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0974-3 · Cited by 66
Emerging proteomics biomarkers and prostate cancer burden in Africa
Adeola, H. A., Blackburn, J. M., Rebbeck, T. R., & Zerbini, L. F. (2017) · Oncotarget · doi:10.18632/oncotarget.16568 · Cited by 26
Metadata
- Authors
- Hernández, J., & Thompson, I. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-08-18
- Volume
- 101
- Issue
- 5
- Pages
- 894-904
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2100531189
- Cited by
- 527
- References
- 67
- FWCI
- 41.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker. https://app.cochat.ai/papers/10.1002/cncr.20480
- The paper
- Hernández, J., & Thompson, I. M. (2004). Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker. Cancer. https://doi.org/10.1002/cncr.20480
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
